The Value of Reputation in Pharmaceuticals
New to the business program: a session for pharmaceutical PR specialists and the GxP News award
One of the most pressing issues in the industry is trust and reputation. Today, publicity is becoming not only a promotional tool but also an indicator of business sustainability. However, publicity requires systematic strategic work to, on the one hand, build a company's image in the eyes of regulators, professional communities, and consumers, and on the other, avoid negative publicity, regulatory risks, and legal issues.
On November 24 (1:15 PM - 3:00 PM), a panel discussion on "Trust as an Asset: The Value of Reputation in Pharmaceuticals" will be held by the industry information publication GxP News.
Key topics for discussion:
• Why do some companies invest in communications, while others deliberately go into the “information shadow”?
• how reputation influences partnerships and dialogue with regulators
• Is it possible to manage trust and reputation in a strict legal environment?
• what is the role of industry media and PR companies in achieving medicinal sovereignty
The session will be held with the support of:
GxP News Award
Before the session, GxP News, as an industry publication, will present a journalism award to industry experts in various categories-for active participation in the business and information space, for proactive stances, and for compelling statements. This year, the award will be presented to experts from associations, pharmaceutical companies, and public organizations-those who shape the GxP community.
You can view the schedule and download a short version below: